Amid the uncertainty around coronavirus vaccines, the Indian Council of Medical Research (ICMR) has claimed that its indigenous vaccine candidate Covaxin has received global attention. "The indigenous vaccine against COVID-19 Covaxin - a product of ICMR-Bharat Biotech collaboration-achieves remarkable feat," the central agency tweeted.
The tweet added that data collated from India shows an "impressive safety and immuno-genicity profile of Covaxin and sparks Lancet's interest in publishing them."
It also stated that promising results in the phase 1 and phase 2 trials of the Bharat Biotech COVID-19 vaccine have led to the phase 3 trials, which are currently underway with 26,000 participants across 22 sites in India.
Covaxin showed long-term antibody and T-cell (immune) memory responses three months after the vaccination in phase 1 trials and tolerable safety responses in phase 2 trials. Bharat Biotech also mentioned the antibodies might remain for 6-12 months, PTI reported.
All India Institute of Medical Sciences (AIIMS), in an advert, also said that AIIMS- New Delhi is a site for Covaxin Phase 3 clinical trial. "This is a whole-virion inactivated vaccine co-sponsored by Indian Council of Medical Research (ICMR) and Bharat Biotech."
The advert adds that those who wish to participate in the COVID-19 vaccine phase 3 trials can send a WhatsApp message at +91-7428847499 or by dropping a mail at firstname.lastname@example.org.